Cargando…

Prognostic Value of Skeletal Muscle Loss in Patients with Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy

SIMPLE SUMMARY: Although reduced skeletal muscle mass affects therapeutic efficacy and adverse events in various therapies for hepatocellular carcinoma (HCC), there are no reports on skeletal muscle mass or its changes and prognostic indications in patients with advanced HCC undergoing hepatic arter...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oura, Kyoko, Morishita, Asahiro, Tani, Joji, Nomura, Takako, Manabe, Takushi, Takuma, Kei, Nakahara, Mai, Tadokoro, Tomoko, Fujita, Koji, Mimura, Shima, Sanomura, Takayuki, Nishiyama, Yoshihiro, Masaki, Tsutomu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047018/ https://www.ncbi.nlm.nih.gov/pubmed/36980720 http://dx.doi.org/10.3390/cancers15061834

Ejemplares similares

Multimodal treatment involving molecular targeted agents and on-demand transcatheter arterial chemoembolization for advanced hepatocellular carcinoma: A case report and review of the literature
por: Oura, Kyoko, et al.
Publicado: (2021)

Usefulness of the Measurement of Psoas Muscle Volume for Sarcopenia Diagnosis in Patients with Liver Disease
por: Manabe, Takushi, et al.
Publicado: (2023)

Peg-IFNα-2a Contributed to HBs Antigen Seroclearance in a Patient with Chronic Hepatitis B Administered Nucleic Acid Analogs: A Three-year Follow-up
por: Tadokoro, Tomoko, et al.
Publicado: (2021)

Efficacy of Combined Therapy with Drug-Eluting Beads-Transcatheter Arterial Chemoembolization Followed by Conventional Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multi-Center Study
por: Morishita, Asahiro, et al.
Publicado: (2021)

Ledipasvir/Sofosbuvir Is Effective for Relapsed Genotype 1b Hepatitis C Virus Patients after Achieving a Sustained Virological Response at Post-treatment Week 12 with Glecaprevir/Pibrentasvir
por: Manabe, Takushi, et al.
Publicado: (2022)

Efficacy of combined modality therapy with sorafenib following hepatic arterial injection chemotherapy and three-dimensional conformal radiotherapy for advanced hepatocellular carcinoma with major vascular invasion
por: Nomura, Takako, et al.
Publicado: (2019)

Relationship between Accurate Diagnosis of Sarcopenia and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Combination Therapy
por: Oura, Kyoko, et al.
Publicado: (2023)

Antitumor Effect of Regorafenib on MicroRNA Expression in Hepatocellular Carcinoma Cell Lines
por: Takuma, Kei, et al.
Publicado: (2022)

Severe Steroid-responsive Skin Disorders Related to Ledipasvir and Sofosbuvir for HCV
por: Tadokoro, Tomoko, et al.
Publicado: (2017)

MicroRNA Interference in Hepatic Host-Pathogen Interactions
por: Morishita, Asahiro, et al.
Publicado: (2021)

MicroRNAs in the Pathogenesis of Hepatocellular Carcinoma: A Review
por: Morishita, Asahiro, et al.
Publicado: (2021)

Giant cutaneous metastasis from hepatocellular carcinoma
por: Morishita, Asahiro, et al.
Publicado: (2022)

Effect of Lenvatinib treatment on the cell cycle and microRNA profile in hepatocellular carcinoma cells
por: Nakahara, Mai, et al.
Publicado: (2022)

Comprehensive analysis of circulating microRNAs as predictive biomarkers for sorafenib therapy outcome in hepatocellular carcinoma
por: Kohno, Tomoki, et al.
Publicado: (2020)

Serum miRNAs Predicting Sustained HBs Antigen Reduction 48 Weeks after Pegylated Interferon Therapy in HBe Antigen-Negative Patients
por: Fujita, Koji, et al.
Publicado: (2018)

Galectin-9 suppresses the tumor growth of colon cancer in vitro and in vivo
por: Morishita, Asahiro, et al.
Publicado: (2021)

Albumin–bilirubin score indicates liver fibrosis staging and prognosis in patients with chronic hepatitis C
por: Fujita, Koji, et al.
Publicado: (2019)

Galectin-9 ameliorates fulminant liver injury
por: Tadokoro, Tomoko, et al.
Publicado: (2017)

Galectin-9 in Gastroenterological Cancer
por: Morishita, Asahiro, et al.
Publicado: (2023)

Aspirin inhibits hepatocellular carcinoma cell proliferation in vitro and in vivo via inducing cell cycle arrest and apoptosis
por: Shi, Tingting, et al.
Publicado: (2020)

Simple scoring system for prediction of hepatocellular carcinoma occurrence after hepatitis C virus eradication by direct-acting antiviral treatment: All Kagawa Liver Disease Group Study
por: Tani, Joji, et al.
Publicado: (2020)

Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model
por: Morishita, Asahiro, et al.
Publicado: (2022)

Association between microRNA-527 and glypican-3 in hepatocellular carcinoma
por: Nomura, Kei, et al.
Publicado: (2021)

MicroRNAs and Nonalcoholic Steatohepatitis: A Review
por: Morishita, Asahiro, et al.
Publicado: (2023)

Cancer Therapy Due to Apoptosis: Galectin-9
por: Fujita, Koji, et al.
Publicado: (2017)

Long-Term Outcomes and Evaluation of Hepatocellular Carcinoma Recurrence after Hepatitis C Virus Eradication by Direct-Acting Antiviral Treatment: All Kagawa Liver Disease Group (AKLDG) Study
por: Tani, Joji, et al.
Publicado: (2021)

Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review
por: Oura, Kyoko, et al.
Publicado: (2021)

Antitumor Effects and Mechanisms of Metabolic Syndrome Medications on Hepatocellular Carcinoma
por: Oura, Kyoko, et al.
Publicado: (2022)

Metformin-suppressed differentiation of human visceral preadipocytes: Involvement of microRNAs
por: Fujita, Koji, et al.
Publicado: (2016)

Hepatocellular carcinoma treated with radical resection after endoscopic diagnosis of the extent of bile duct invasion: A case report
por: Sato, Yudai, et al.
Publicado: (2023)

Prediction of Transplant-Free Survival through Albumin-Bilirubin Score in Primary Biliary Cholangitis
por: Fujita, Koji, et al.
Publicado: (2019)

Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study
por: Morishita, Asahiro, et al.
Publicado: (2022)

Circulating microRNA-636 is associated with the elimination of hepatitis C virus by ombitasvir/paritaprevir/ritonavir
por: Morishita, Asahiro, et al.
Publicado: (2018)

Fibrosis Staging Using Direct Serum Biomarkers is Influenced by Hepatitis Activity Grading in Hepatitis C Virus Infection
por: Fujita, Koji, et al.
Publicado: (2018)

Verification of B-lymphocyte activating factor’s involvement in the exacerbation of insulin resistance as well as an autoimmune response in patients with nonalcoholic steatohepatitis and patients with HCV-related chronic liver disease
por: Himoto, Takashi, et al.
Publicado: (2017)

Clinical impact of antibodies to Sp100 on a bacterial infection in patients with primary biliary cholangitis
por: Himoto, Takashi, et al.
Publicado: (2021)

Albumin–Bilirubin Score Differentiates Liver Fibrosis Stage and Hepatocellular Carcinoma Incidence in Chronic Hepatitis B Virus Infection: A Retrospective Cohort Study
por: Fujita, Koji, et al.
Publicado: (2019)

Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells
por: Shi, Tingting, et al.
Publicado: (2021)

Molecular and Functional Roles of MicroRNAs in the Progression of Hepatocellular Carcinoma—A Review
por: Oura, Kyoko, et al.
Publicado: (2020)

The Roles of Epigenetic Regulation and the Tumor Microenvironment in the Mechanism of Resistance to Systemic Therapy in Hepatocellular Carcinoma
por: Oura, Kyoko, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_m769rs9151338k4ik0hr3g7q8q